
    
      This prospective, multi-center, single-arm feasibility study is planned to assess the safety
      and patient tolerance of Biolen for the localized delivery of bicalutamide into the prostate
      in patients presenting for treatment of prostate cancer. Study participants will have
      placement of the drug eluting Biolen and be followed through scheduled radical prostatectomy.
    
  